Physician profile
Holly Hapner
NPI 1093179699
$6,185.98
in general payments reported to CMS, 2019-2025
36 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $558 · 2020: $937 · 2021: $669 · 2022: $1,053 · 2023: $943 · 2024: $1,011 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,969.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,337.98 | 2019-2025 | |
| Novo Nordisk INC | $1,063.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $637.43 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Axsome Therapeutics, INC. | $475.32 | 2024-2025 | Auvelity |
| Amarin Pharma, INC. | $350.36 | 2019-2022 | |
| Exact Sciences Corporation | $332.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $239.76 | 2019-2022 | |
| Pfizer INC. | $207.88 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $157.73 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $139.77 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $114.04 | 2023-2025 | Gemtesa |
| Allergan, INC. | $105.69 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $98.16 | 2020-2021 | |
| Amgen INC. | $87.70 | 2019-2023 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $81.50 | 2022-2025 | Arexvy, Shingrix, Penmenvy |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $81.26 | 2022-2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $80.13 | 2022-2025 | Zepbound, Emgality, Mounjaro |
| Novartis Pharmaceuticals Corporation | $73.18 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $68.33 | 2019-2022 | |
| Eisai INC. | $67.66 | 2020-2021 | |
| Mylan Specialty L.P. | $50.78 | 2023 | Yupelri |
| Daiichi Sankyo INC. | $43.75 | 2021 | |
| Sanofi-Aventis U.S. LLC | $40.15 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.45 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.73 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.60 | 2020-2022 | |
| Alkermes, INC. | $27.50 | 2023 | Vivitrol |
| Abbott Laboratories | $18.89 | 2019 | |
| Amag Pharmaceuticals, INC. | $16.18 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.19 | 2024 | Voquezna |
| Hikma Pharmaceuticals USA | $14.89 | 2019 | |
| Bausch Health US, LLC | $14.36 | 2022 | |
| Genentech USA, INC. | $12.60 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $12.57 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.50 | 2021 | |
| Corium, LLC | $6.30 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Hapner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.